CLN-049 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Myelodysplastic Syndrome. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CLN-049’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for CLN-049 is expected to reach an annual total of $52 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CLN-049 Overview
CLN-049 is under development for the treatment of relapsed or refractory acute myelocytic leukemia and myelodysplastic syndrome. The drug candidate is a Bi-specific T-cell engager (BiTE) monoclonal antibody acts by targeting fms-like tyrosine kinase 3 (FLT3) and CD3. It is administered through intravenous and subcutaneous route.
Cullinan Therapeutics Overview
Cullinan Therapeutics, formerly Cullinan Oncology Inc, is a clinical-stage biotechnology company that focuses on developing oncology therapies for cancer patients. Its CLN-619, is a monoclonal antibody, which treats solid tumors; CLN-049, is a humanized bispecific antibody for acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator, which targets multiple solid tumors; Zipalertinib, a bioavailable small-molecule, which treats patients with non-small cell lung cancer; CLN-617, a fusion protein for solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed or refractory B-cell non-Hodgkin lymphoma. Cullinan Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$191.1 million in FY2023, compared to an operating profit of US$144.7 million in FY2022. The net loss of the company was US$153.2 million in FY2023, compared to a net profit of US$111.2 million in FY2022.
For a complete picture of CLN-049’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
